A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia

Hematological Oncology

Volumn 22, Issue 2, 2004, Pages 43-53

  Koc, Yener ^a   Oyan, Basak ^a   Kars, Ayse ^a   Tekuzman, Gulten ^a   Canpinar, Hande ^a   Kansu, Emin ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Acute myeloblastic leukemia; Continuous infusion; Mitoxantrone; Survival

Indexed keywords

AMIKACIN; ANTIFUNGAL AGENT; CEFTAZIDIME; CYTARABINE; METOCLOPRAMIDE; MITOXANTRONE;

ABDOMINAL PAIN; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ALLERGY; ALOPECIA; BOLUS INJECTION; BONE MARROW SUPPRESSION; BRADYCARDIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FEVER; FOLLOW UP; GRANULOCYTOPENIA; HEART EJECTION FRACTION; HUMAN; HYPOTENSION; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SKIN TOXICITY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE COUNT; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MITOXANTRONE; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 6944235689     PISSN: 02780232     EISSN: None     Source Type: Journal    
DOI: 10.1002/hon.726     Document Type: Review

References (33)

1. Walters RS, Kantarjian HM, Keating MJ, et al. Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia. Cancer 1988; 62: 677-682.
2. White RJ, Durr FE. Development of mitoxantrone. Invest New Drugs 1985; 3: 85-93.
3. Durr FE, Wallace RE, Citarella RV. Molecular and biochemical pharmacology of mitoxantrone. Cancer Treat Rev 1983; 10(Suppl. B): 3-11.
4. Smith WJ, Muss HB, Capizzi RL, et al. Mitoxantrone and high-dose ara-C in refractory malignancies: a phase I trial. Med Pediatr Oncol 1989; 17: 159-163.
5. Alberts DS, Peng YM, Bowden GT, Dalton WS, Mackel C. Pharmacology of mitoxantrone: mode of action and pharmacokinetics. Invest New Drugs 1985; 3: 101-107.
6. Crespi MD, Ivanier SE, Genovese J, Baldi A. Mitoxantrone affects topoisomerase activities in human breast cancer cells. Biochem Biophys Res Commun 1986; 136: 521-528.
7. Paciucci PA, Cuttner J, Holland JF. Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia. Semin Oncol 1984; 11: 36-40.
8. Hiddemann W, Kreutzmann H, Straif K, et al. High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia. Blood 1987; 69: 744-749.
9. Keating MJ, Estey E, Kantarjian HM, et al. Comparison of results of salvage therapy in adult acute myelogenous leukemia. Acta Haematol 1987; 78(Suppl. 1): 120-126.
10. Paciucci PA, Dutcher JP, Cuttner J, Straumann JJ, Wiernik PH, Holland JF. Mitoxantrone and Ara-C in previously treated patients with acute myelogenous leukemia. Leukemia 1987; 1: 565-567.
11. Brito-Babapulle F, Catovsky D, Slocombe G, et al. A phase II study of mitoxantrone and cytarabine in acute myeloid leukemia. Cancer Treat Rep 1987; 71: 161-163.
12. Lowenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy-the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol 1998; 16: 872-881.
13. Amadori S, Meloni G, Petti MC, Papa G, Miniero R, Mandelli F. Phase II trial of intermediate dose ARA-C (IDAC) with sequential mitoxantrone (MITOX) in acute myelogenous leukemia. Leukemia 1989; 3: 112-114.
14. Reece DE, Elmongy MB, Barnett MJ, Klingemann HG, Shepherd JD, Philips GL. Chemotherapy with high-dose cytosine arabinoside and mitoxantrone for poor-prognosis myeloid leukemias. Cancer Invest 1993; 11: 509-516.
15. Bow EJ, Sutherland JA, Kilpatrick MG, et al. Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide. J Clin Oncol 1996; 14: 1345-1352.
16. Pavlovsky S, Gonzalez Llaven J, Garcia Martinez MA, et al. A randomized study of mitoxantrone plus cytarabine versus daunomycin plus cytarabine in the treatment of previously untreated adult patients with acute nonlymphocytic leukemia. Ann Hematol 1994; 69: 11-15.
17. Greidanus J, de Vries EG, Nieweg MB, de Langen ZJ, Willemse PH. Evaluation of a totally implanted venous access port and portable pump in a continuous chemotherapy infusion schedule on an outpatient basis. Eur J Cancer Clin Oncol 1987; 23: 1653-1657.
18. Kaminer LS, Choi KE, Daley KM, Larson RA. Continuous infusion mitoxantrone in relapsed acute nonlymphocytic leukemia. Cancer 1990; 65: 2619-2623.
19. Stewart DJ, Green RM, Mikhael NZ, Monpetit V, Thibault M, Maroun JA. Human autopsy tissue concentrations of mitoxantrone. Cancer Treat Rep 1986; 70: 1255-1261.
20. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of French-American- British Cooperative Group. Ann Intern Med 1985; 103: 620-625.
21. Benjamin RS, Chawla SP, Ewer MS, Garrasco CH, Mackay B, Holmes F. Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update. Invest New Drugs 1985; 3: 117-121.
22. Coleman RE, Maisey MN, Knight RK, Rubens RD. Mitoxantrone in advanced breast cancer-a phase II study with special attention to cardiotoxicity. Eur J Cancer Clin Oncol 1984; 20: 771-776.
23. National Cancer Institute. Common toxicity criteria manual. Available at: http.//ncictep.cancer.gov 1999. Accessed 1 Aug 2002.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
25. Peto R, Peto J. Asymptomatically efficient rank invariant test procedures. J R Stat Soc A 1972; 135: 185-206.
26. Greidanus J, de Vries EG, Mulder NH, et al. A phase I pharmacokinetic study of 21-day continuous infusion mitoxantrone. J Clin Oncol 1989; 7: 790-797.
27. Greidanus J, Willemze PH, Uges DR, Oremus ET, de Langen ZJ, de Vries EG. Continuous infusion of low-dose doxorubicin, epirubicin and mitoxantrone in cancer chemotherapy: a review. Pharm Weekbl Sci 1988; 10: 237-245.
28. Koc Y, Akpek G, Kansu E, et al. Bolus and continuous infusion mitoxantrone in newly diagnosed adult acute lymphoblastic leukemia: results of two consecutive phase II clinical studies. Cancer Invest 1998; 16: 355-365.
29. Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin toxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96: 133-139.
30. Anderson KC, Garnick MB, Meshad MW, et al. Phase I trial of mitoxantrone by 24-hour continuous infusion. Cancer Treat Rep 1983; 67: 435-438.
31. Rowland CG, Sewell G. Optimal drug delivery: a phase I study of continuously infused mitoxantrone. Procc ECCO 1987; 4: A441.
32. Cassileth PA, Lynch E, Hines JD, et al. Varying intensity postremission therapy in acute myeloid leukemia. Blood 1992; 79: 1924-1930.
33. Mayer RJ, Davis RB, Schiffer CA, et al. for the Cancer and Leukemia Group B. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994; 331: 896-903.